“…"SIDU" Profile and Catalysts SIDU is reported in several countries including the United Kingdom; United States; Australia; the Netherlands; France; Spain; Portugal; Thailand; Ireland; Czech Republic; Germany; Denmark; Finland and Greece (Glynn et al, 2018;Guadamuz & Boonmongkon, 2018;Hopwood, Drysdale, & Treloar, 2018;Knoops, Bakker, Van Bodegom, & Zantkuijl, 2015;Wendel, 2011). Reported prevalence figures for MSM engaging in "SIDU" range between 1% and 50% (Bourne, Reid, Hickson, Torres-Rueda, & Weatherburn, 2015;Elliot, Singh, Tyebally, Gedela, & Nelson, 2017;Frankis & Clutterbuck, 2017;Frankis, Flowers, McDaid, & Bourne, 2018;Molina et al, 2018;Power et al, 2018). In a population of HIV-positive MSM recruited through UK health clinics, Pufall et al (2018) found that a minority of MSM reported engaging in SIDU: 10.1% (any drug); 4% (multiple drugs); 6.7% (methamphetamine); 0.4% (GHB/GBL); ketamine (1.1%) and mephedrone (6.6%).…”